Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of BioTTT001 in recurrent or progressive high-grade glioma
CTR20244638Phase 2Active
- Sponsor
- Triton Biopharma
- Start
- Dec 2024
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of BioTTT001 in glioma, sponsored by Triton Biopharma. Started Dec 2024; status: active.
02
Drugs
BioTTT001
03
Conditions
glioma
Beyond the preview
Go deeper on CTR20244638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244638.